PMID- 27384068 OWN - NLM STAT- MEDLINE DCOM- 20170210 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 39 IP - 2 DP - 2016 TI - Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung. PG - 544-53 LID - 10.1159/000445646 [doi] AB - BACKGROUND/AIMS: Adeno-associated virus (AAV) vectors are being increasingly used as the vector of choice for in vivo gene delivery and gene therapy for many pulmonary diseases. Recently, it was shown that phosphorylation of surface-exposed tyrosine residues from AAV capsid targets the viral particles for ubiquitination and proteasome-mediated degradation, and mutations of these tyrosine residues lead to highly efficient vector transduction in vitro and in vivo in different organs. In this study, we evaluated the pulmonary transgene expression efficacy of AAV9 vectors containing point mutations in surface-exposed capsid tyrosine residues. METHODS: Eighteen C57BL/6 mice were randomly assigned into three groups: (1) a control group (CTRL) animals underwent intratracheal (i.t.) instillation of saline, (2) the wild-type AAV9 group (WT-AAV9, 1010 vg), and (3) the tyrosine-mutant Y731F AAV9 group (M-AAV9, 1010 vg), which received (i.t.) self-complementary AAV9 vectors containing the DNA sequence of enhanced green fluorescence protein (eGFP). Four weeks after instillation, lung mechanics, morphometry, tissue cellularity, gene expression, inflammatory cytokines, and growth factor expression were analyzed. RESULTS: No significant differences were observed in lung mechanics and morphometry among the experimental groups. However, the number of polymorphonuclear cells was higher in the WT-AAV9 group than in the CTRL and M-AAV9 groups, suggesting that the administration of tyrosine-mutant AAV9 vectors was better tolerated. Tyrosine-mutant AAV9 vectors significantly improved transgene delivery to the lung (30%) compared with their wild-type counterparts, without eliciting an inflammatory response. CONCLUSION: Our results provide the impetus for further studies to exploit the use of AAV9 vectors as a tool for pulmonary gene therapy. CI - (c) 2016 The Author(s) Published by S. Karger AG, Basel. FAU - Martini, Sabrina V AU - Martini SV AD - Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Ilha do Fundx00E3;o, Brazil. FAU - Silva, Adriana L AU - Silva AL FAU - Ferreira, Debora AU - Ferreira D FAU - Rabelo, Rafael AU - Rabelo R FAU - Ornellas, Felipe M AU - Ornellas FM FAU - Gomes, Karina AU - Gomes K FAU - Rocco, Patricia R M AU - Rocco PR FAU - Petrs-Silva, Hilda AU - Petrs-Silva H FAU - Morales, Marcelo M AU - Morales MM LA - eng PT - Journal Article DEP - 20160707 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Capsid Proteins) RN - 0 (Cytokines) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 147336-22-9 (Green Fluorescent Proteins) RN - 42HK56048U (Tyrosine) SB - IM MH - Animals MH - Capsid Proteins/*genetics MH - Cytokines/genetics/metabolism MH - Dependovirus/*genetics MH - Gene Expression MH - Genetic Therapy/methods MH - Genetic Vectors/genetics MH - Green Fluorescent Proteins/genetics/metabolism MH - Intercellular Signaling Peptides and Proteins/genetics/metabolism MH - Lung/*metabolism MH - Male MH - Mice, Inbred C57BL MH - *Point Mutation MH - Random Allocation MH - Reverse Transcriptase Polymerase Chain Reaction MH - Transfection/*methods MH - Transgenes/genetics MH - Tyrosine/*genetics EDAT- 2016/07/08 06:00 MHDA- 2017/02/12 06:00 CRDT- 2016/07/08 06:00 PHST- 2016/05/31 00:00 [accepted] PHST- 2016/07/08 06:00 [entrez] PHST- 2016/07/08 06:00 [pubmed] PHST- 2017/02/12 06:00 [medline] AID - 000445646 [pii] AID - 10.1159/000445646 [doi] PST - ppublish SO - Cell Physiol Biochem. 2016;39(2):544-53. doi: 10.1159/000445646. Epub 2016 Jul 7.